Evidence map›Paper›PMID 40523762›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2025

MiR

Hui Zhou, Meng Wu, Shaihong Zhu, Yi Zhang

Abstract read
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hui ZhouDepartment of Gastrointestinal Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China. oneonedreame@gmail.com.
Meng WuDepartment of Dermatology, Hunan Provincial People's Hospital, Changsha 410002, China.
Shaihong ZhuDepartment of Gastrointestinal Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Yi ZhangDepartment of Gastrointestinal Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China. drzhy@aliyun.com.

Funding

the National Natural Science Foundation 82072729This is an open access article under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International CC BY-NC-ND 4.0 and //creativecommons.org/licenses/by-nc-nd/4.0/Wuhan Municipal Health Commission Medical Research Project WX19Q30
6 · The paper itself

Abstract

objectivesOxaliplatin (OXA) and 5-fluorouracil (5-FU) are 2 commonly used chemotherapeutic agents for colorectal cancer (CRC). MicroRNAs (miRNAs, miRs) play crucial roles in the development of chemoresistance in various cancers. However, the role and mechanism of miR-224-5p in regulating CRC chemoresistance remain unclear. This study aims to investigate the function of miR-224-5p in chemoresistant CRC cells and the underlying mechanisms.

methodsCRC datasets GSE28702 and GSE69657 were downloaded from the Gene Expression Omnibus (GEO) database. Differentially expressed miRNAs between drug-sensitive and resistant groups (OXA or 5-FU) were analyzed, and miR-224-5p was identified as the target miRNA. Chemoresistant cell lines HCT15-OXR, HCT15-5-FU, SW480-OXR, and SW480-5-FU were established. Transient transfections were performed using miR-224-5p mimics, inhibitors, and their respective negative controls (control mimic, control inhibitor) in these cell lines. Cells were treated with different concentrations of OXA or 5-FU post-transfection, and the half-maximal inhibitory concentration (IC

resultsChemoresistant CRC cells exhibited down-regulated miR-224-5p expression, whereas up-regulation of miR-224-5p enhanced chemotherapy sensitivity. Exposure to OXA or 5-FU significantly increased autophagic activity in chemoresistant CRC cells, which was reversed by miR-224-5p overexpression. Dual-luciferase assays verified Bcl-2 as a direct target of miR-224-5p.

conclusionsMiR-224-5p regulates chemoresistance in CRC by modulating autophagy through direct targeting of Bcl-2.

Indexed as

AutophagyColorectal NeoplasmsDrug Resistance, NeoplasmMicroRNAsProto-Oncogene Proteins c-bcl-2Cell Line, TumorFluorouracilGene Expression Regulation, NeoplasticHumansOxaliplatinFluorouracilMicroRNAsMIRN224 microRNA, humanOxaliplatinProto-Oncogene Proteins c-bcl-2autophagyB-cell lymphoma-2chemoresistancecolorectal cancermiR-224-5p

Identifiers

PMID40523762
PMCPMC13346000

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.